Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Lowered to $205.00 at Needham & Company LLC

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective cut by Needham & Company LLC from $208.00 to $205.00 in a research report released on Thursday, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also recently issued reports on the stock. Morgan Stanley lowered their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an equal weight rating on the stock in a report on Friday, July 12th. The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They issued a buy rating and a $169.00 price target on the stock. Barclays reduced their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an overweight rating for the company in a research note on Friday, May 3rd. Cantor Fitzgerald reiterated an overweight rating and issued a $180.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Finally, HC Wainwright reiterated a buy rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of Moderate Buy and a consensus target price of $175.20.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded down $2.06 during trading hours on Thursday, hitting $111.20. The company’s stock had a trading volume of 238,932 shares, compared to its average volume of 683,345. The business has a 50 day simple moving average of $107.82 and a two-hundred day simple moving average of $114.05. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $146.70. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 1.90. The company has a market cap of $7.01 billion, a price-to-earnings ratio of 19.65, a PEG ratio of 1.76 and a beta of 0.58.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Large investors have recently modified their holdings of the stock. Rise Advisors LLC boosted its stake in Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares during the last quarter. Versant Capital Management Inc lifted its position in Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 269 shares during the period. GAMMA Investing LLC grew its position in Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares during the period. Gladius Capital Management LP purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at $33,000. Finally, Cape Investment Advisory Inc. boosted its stake in shares of Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after buying an additional 292 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.